Cassuto Daniel, Pignatti Marco, Pacchioni Lucrezia, Boscaini Giulia, Spaggiari Antonio, De Santis Giorgio
Modena and Milan, Italy.
From the Department of Plastic and Reconstructive Surgery, Policlinico di Modena, University of Modena and Reggio Emilia; and private practice, Piazza Cinque Giornate 1, Milano.
Plast Reconstr Surg. 2016 Aug;138(2):215e-227e. doi: 10.1097/PRS.0000000000002350.
Nonresorbable substances are still injected to enhance soft-tissue volumes and fill subcutaneous defects. Inflammatory reactions (often termed granulomas) to these materials can be functionally and socially disabling. Most therapeutic options used until now are nonspecific antiinflammatory treatments, targeting an ill-defined immune reaction of undefined cause. The minimally invasive intralesional laser treatment can remove the foreign substance and the inflammatory reaction with an 808-nm diode laser.
Two hundred nineteen consecutive patients referred from September of 2006 until June of 2013 for inflammatory reactions to permanent facial fillers and treated with this technique at the authors' institution with a minimum 6-month follow-up were studied. All patients were screened with an ultrasound soft-tissue examination and the lesions were classified as either cystic (implants inserted by bolus injections) or infiltrating (as in microdeposit injection). The authors' therapeutic approach is summarized in an algorithm: infiltrating patterns were treated with intralesional laser treatment alone, whereas cystic distribution cases were also drained through stab wound incisions. The mean patient age was 49 years (range, 23 to 72 years); 204 patients were women.
Partial improvement was obtained in 30 percent of patients, whereas 8 percent discontinued the treatment because of a lack of satisfaction. Lesions disappeared completely in 62 percent. Complications included transient swelling in all cases, hematoma in 2 percent, secondary sterile abscess in 9.5 percent, and minimal scarring in 10 percent.
A problem-oriented systematic approach to inflammatory complications from permanent fillers is proposed, based on the comprehensive work from the past 7 years, with an overall improvement rate of 92 percent.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
目前仍在注射不可吸收物质以增加软组织容量和填充皮下缺损。这些材料引发的炎症反应(通常称为肉芽肿)会对功能和社交造成障碍。到目前为止,大多数治疗方法都是非特异性抗炎治疗,针对的是病因不明、定义不清的免疫反应。微创病灶内激光治疗可使用808纳米二极管激光去除异物和炎症反应。
对2006年9月至2013年6月期间因永久性面部填充剂炎症反应而转诊至作者所在机构并接受该技术治疗且随访至少6个月的219例连续患者进行研究。所有患者均接受超声软组织检查,病变分为囊性(通过推注注射植入物)或浸润性(如微沉积注射)。作者的治疗方法总结在一个算法中:浸润性模式仅采用病灶内激光治疗,而囊性分布病例还通过刺伤切口引流。患者平均年龄为49岁(范围23至72岁);204例患者为女性。
30%的患者获得部分改善,8%的患者因不满意而停止治疗。62%的病变完全消失。并发症包括所有病例均出现的短暂肿胀、2%的血肿、9.5%的继发性无菌脓肿以及10%的轻微瘢痕形成。
基于过去7年的综合工作,提出了一种针对永久性填充剂炎症并发症的以问题为导向的系统方法,总体改善率为92%。
临床问题/证据级别:治疗性,IV级。